Further data from the pivotal Checkmate 816 trial continue to support the combination of nivolumab with chemotherapy in the neoadjuvant setting for patients with resectable non–small cell lung cancer.
Medscape Medical News
Preop Nivoulmab Plus Chemo 'a Quantum Leap' in NSCLC Therapy
